The global Oncology/Cancer Drugs market generated USD 146.72 billion revenue in 2022 and is projected to grow at a CAGR of 7.83% from 2023 to 2032. The market is expected to reach USD 311.81 billion by 2032. The expansion of the market is propelled by a rise in the prevalence of cancer diseases and an increase in the incidence of different cancer diseases. The growing demand for advanced therapies, such as targeted and biological drug therapies, and a significant increase in the global geriatric population further contribute to this growth. Additionally, the heightened awareness of cancer and the early screening of the disease also play pivotal roles in fostering the development of the oncology drugs market.
